Strong third quarter helps Abbott shares climb
This article was originally published in Clinica
Abbott’s share price increased 3% in one day, following positive third-quarter results. Shares closed at $51.20 on the NYSE on October 14, up from $49.65 the previous day. The Abbott Park, Illinois-based firm recorded revenue of $7.8bn for the period, an increase of 4% over sales of $7.5bn from the period in 2008. This growth was driven by a 6% increase in worldwide diagnostics sales to $909m and an 8% growth in global vascular sales to $666m. Net income also improved – up by around 36% to $1.5bn. The bottom line was aided as cost of products, R&D, operating expenditure and general costs stayed largely flat. The firm’s chairman and CEO, Miles White, said that the results were higher than expected.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals